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Randomized Comparison of Sirolimus
and Paclitaxel Drug-Eluting Stents for Long
Lesions in the Left Anterior Descending Artery
An Intravascular Ultrasound Study
Anna Sonia Petronio, MD, Marco De Carlo, MD, PHD, Giulia Branchitta, MD, Barbara Papini, RT,
Nicola Ciabatti, MD, PHD, Roberto Gistri, MD, Bernardo Cortese, MD, Gherardo Gherarducci, MD,
Antonio Barsotti, MD
Pisa, Italy
Objectives The goal of this work was to verify whether the superiority of the sirolimus-eluting stent (SES) in inhibiting neoin-
timal hyperplasia could be demonstrated in complex coronary lesions.
Background Both the SES (Cypher, Cordis, Miami Lakes, Florida) and the paclitaxel-eluting stent (PES) (Taxus, Boston Scien-
tific, Natick, Massachusetts) have shown a marked reduction in neointimal hyperplasia compared with bare-
metal stents. Intravascular ultrasound (IVUS) is the best method to assess arterial response to stent deployment,
but few IVUS data are available comparing complex lesions treated with SES or PES.
Methods We prospectively randomized patients with complex lesions to SES or PES implantation. Intravascular ultrasound
and quantitative angiography were performed post-procedure and at 9 months. Mean neointimal hyperplasia
area (NIHA), percent of NIHA (NIHA%), mean peristent plaque area (PSPA), and percent of PSPA (PSPA%) were
calculated. The primary end point was NIHA% at follow-up. Secondary end points included change in PSPA% and
angiographic late luminal loss at follow-up.
Results Of the 100 patients enrolled, 42 receiving the SES and 43 receiving the PES had adequate IVUS assessment.
Vessel, plaque, and lumen areas were comparable at follow-up, but NIHA% was significantly lower with SES than
PES (7.4  4.2% vs. 15.4  8.1%; p  0.001). A significant reduction in PSPA% was observed with SES (4  10%
vs. 0  8%; p  0.01). Late loss was significantly lower with SES (0.16 0.19 mm vs. 0.32  0.33 mm; p  0.003).
Conclusions The SES shows a significantly higher inhibition of neointimal hyperplasia compared with PES in complex lesions.
However, both stents have excellent IVUS and angiographic results at 9 months. A significant reduction in peri-
stent plaque is observed only with SES. (J Am Coll Cardiol 2007;49:539–46) © 2007 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.09.042o
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soth the sirolimus-eluting stent (SES) (Cypher, Cordis,
iami Lakes, Florida) (1,2) and the paclitaxel-eluting stent
PES) (Taxus, Boston Scientific, Natick, Massachusetts) (3)
ave shown a striking reduction in neointimal hyperplasia
ompared with bare-metal stents based on angiographic
ssessments. However, 2-dimensional angiography only
epicts luminal characteristics of vessels. Volumetric intra-
ascular ultrasound (IVUS) provides unique information
egarding the vascular responses to stent implantation. In
articular, IVUS allows quantification of neointimal hyper-
lasia and of vessel remodeling (2). Few data are available
rom the Cardiology Unit, Cardiothoracic Department, University of Pisa, Pisa,
taly.s
Manuscript received July 5, 2006; revised manuscript received September 22, 2006,
ccepted September 27, 2006.n IVUS assessment of long, complex coronary lesions
reated with the SES or the PES, and to date no random-
zed comparison of IVUS findings has been reported in
hese subjects. A comparison of IVUS reports involving
hort lesions treated with the SES (4–8) or the PES
3,9,10) shows that the SES appears to exert a more
owerful inhibition of neointimal growth. The objective of
his study was to verify whether the superiority of the SES
n inhibiting neointimal hyperplasia could be demonstrated
n complex coronary lesions.
ethods
atient selection. Patients with stable angina, non–ST-
egment elevation acute coronary syndrome, or documented
ilent ischemia undergoing coronary angiography at Pisa Uni-
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Cypher Versus Taxus in Complex Lesions: The IVUS Study February 6, 2007:539–46versity Hospital were screened
for enrollment. Inclusion criteria
were: 1) presence of an angio-
graphically significant stenosis in
the proximal and/or mid-portion
of the left anterior descending
artery; 2) American College of
Cardiology/American Heart As-
sociation lesion class B2 or C,
requiring a stent 16 mm in
length; 3) vessel reference diam-
eter between 2.5 and 3.7 mm at
lesion site; and 4) consent to
undergo a follow-up angiography
at 9 months. Exclusion criteria
were: 1) ST-segment elevation
acute myocardial infarction; 2)
intolerance to aspirin or clopi-
dogrel; 3) severe comorbidity;
and 4) participation in another
clinical study. The study com-
plied with the Declaration of
elsinki and was approved by the local ethics committee.
ll patients gave written informed consent.
andomization and treatment. Randomization was per-
ormed after diagnostic angiography and before angioplasty.
equentially numbered, sealed randomization envelopes
ere used, with a computer-generated random allocation
equence. Patients were randomized on a 1:1 basis to
reatment with an SES (Cypher) or a PES (Taxus). Stent
iameter ranged from 2.75 to 3.50 mm; minimum stent
ength was 18 mm for the SES and 16 mm for the PES.
horter stents could be used as a second stent for complete
esion coverage, or to treat edge dissection. In case of
nability to deliver a single stent to cover the whole length of
he lesion, the use of 2 shorter stents with overlapping edges
as allowed. If a mixture of drug-eluting stents could not be
voided, the patient was excluded from the study.
Before percutaneous coronary intervention (PCI), all
atients received100 mg of aspirin, and a 300-mg loading
ose of clopidogrel was administered before or at the time of
CI. Percutaneous coronary intervention was performed
sing a standard technique with unfractionated heparin
70 U/kg of body weight). Use of glycoprotein IIb/IIIa
nhibitors was at the physician’s discretion. Successful in-
ervention was defined as a patent vessel with antegrade
hrombolysis In Myocardial Infarction (TIMI) flow grade
and angiographic residual stenosis 50%. Patients were
ischarged on aspirin 100 mg daily indefinitely, and clopi-
ogrel 75 mg daily for6 months after PCI. In addition, all
atients were discharged on simvastatin indefinitely, at a
aily dose of 20 or 40 mg, as necessary to obtain low-density
ipoprotein cholesterol levels of 110 mg/dl.
VUS analysis. A commercially available IVUS system
Boston Scientific) was used. All IVUS studies were per-
Abbreviations
and Acronyms
IVUS  intravascular
ultrasound
LL  late luminal loss
MLA  minimal lumen area
MLD  minimal luminal
diameter
NIHA  mean neointimal
hyperplasia area
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent
PSPA  mean peristent
plaque area
RVD  reference vessel
diameter
SES  sirolimus-eluting
stentormed at the end of the procedure, after the intracoronary ddministration of nitroglycerin 200 g. The IVUS catheter
as advanced at least 10 mm distal to the stent, and imaging
as performed to at least 10 mm proximal to the stent, with
motorized transducer pullback speed of 0.5 mm/s. Intra-
ascular ultrasound images were recorded onto S-VHS tape
nd analyzed by 2 expert readers blinded to the treatment
rm, with intraobserver and interobserver agreements of r
.96 and r 0.91, respectively. The interobserver variability
as assessed comparing the measurement of lumen volume
n 15 recordings. Intraobserver variability was assessed by
eanalyzing 15 recordings 1 month after the initial analysis.
ntravascular ultrasound characteristics were identified ac-
ording to the criteria of the American College of Cardiol-
gy Clinical Expert Consensus document on IVUS (11),
sing computerized planimetry (Tapemeasure, Indec Inc.,
ountain View, California).
The external elastic membrane, stent, and lumen con-
ours were identified, both at baseline and follow-up, every
illimeter within the stented segment by semiautomatic
etection contour mode. When the external elastic mem-
rane could not be identified (due to acoustic shadowing)
ver a 90° arc, it was not measured. If the external elastic
embrane could not be measured in 75% of the stent
ength, the patient was excluded from the study. The total
essel volume, stent volume, and lumen volume were mea-
ured, and the mean vessel area, mean stent area, and mean
umen area were calculated as the ratio of the corresponding
olume to the analyzed length. The minimal lumen area
MLA) was also measured. The length of each stent that
as free of IVUS-detectable neointimal hyperplasia was
etermined. The following parameters were calculated:
ean peristent plaque area (PSPA) (defined as [vessel area]
[stent area], PSPA% (defined as PSPA/[vessel area] 
00), mean neointimal hyperplasia area (NIHA) (defined as
stent area]  [lumen area] at follow-up), and NIHA%
defined as NIHA/[stent area]  100). Minimal in-stent
umen area after implantation was considered optimal when
6 mm2 (12).
Incomplete stent apposition was defined as a separation
f at least 1 stent strut from the intimal surface of the
rterial wall. Incomplete apposition at 9 months was con-
idered “persistent” if already present post-procedure, and
late-acquired” if it was not present after implantation (13).
uantitative coronary angiography. Coronary angio-
rams at baseline, immediately after PCI, and at follow-up
ere performed in at least 2 orthogonal views after intra-
oronary administration of nitroglycerin 0.2 mg. Care was
aken to avoid vessel overlapping and to obtain the same
iews at baseline and follow-up. Angiograms were analyzed
y 2 experienced readers, unaware of treatment allocation, with
he use of an automated edge-detection system (Quantcor
iemens System, Siemens AG, Erlangen, Germany). The
ntraobserver and interobserver agreements were r  0.95
nd r  0.88, respectively. The interobserver variability was
ssessed comparing the measurement of minimal lumen
iameter in 15 angiograms. Intraobserver variability was
a
i
v
(
R
[
g
w
m
S
t
P
1
a
b
c
v
i
l
T
t
S
d
c
6
m
t
(
c
7
C
d
c
f
c
C
f
W
c
e
N
g
s
R
B
e
541JACC Vol. 49, No. 5, 2007 Petronio et al.
February 6, 2007:539–46 Cypher Versus Taxus in Complex Lesions: The IVUS Studyssessed by reanalyzing 15 angiograms 1 month after the
nitial analysis. Parameters measured were the reference
essel diameter (RVD), the minimal luminal diameter
MLD), the percent stenosis (defined as [RVD  MLD]/
VD  100), and the late luminal loss (LL) (defined as
MLD after PCI]  [MLD at follow-up]). All angio-
raphic measurements of the target lesion were obtained
ithin the stent and within its proximal and distal 5-mm
argins.
tudy end points. The primary prespecified end point was
he comparison of NIHA% at follow-up between SES and
ES use. Secondary end points included the comparison of:
) change in PSPA% from baseline to follow-up; and 2)
ngiographic LL at follow-up.
Major adverse cardiac events were assessed at 9 months,
ut were not an end point. They included death from
ardiac causes, myocardial infarction, and target-lesion re-
ascularization. Myocardial infarction was defined as an
ncrease in creatine kinase to more than twice the upper
imit of the normal range, with elevation of troponin I.
arget-lesion revascularization was defined as revasculariza-
ion for a stenosis within the stent or its 5-mm borders.
tatistical analysis. At the time of study design, IVUS
ata on the SES and the PES in the literature involved short
oronary lesions in small populations, with a NIHA% of
Figure 1 Flow of Participants Through the Study
IVUS  intravascular ultrasound; PES  paclitaxel-eluting stent; SES  sirolimus-e.6  5.5% for the SES (5), and of 7.8  9.9% (0.7  0.9
m2) for the PES (3). Since total stented length increases
he risk of in-stent restenosis also for drug-eluting stents
14), we anticipated a 60% increase in NIHA% in long,
omplex lesions. Thus, a NIHA% of 9  5% and of 13 
% with the SES and the PES, respectively, was anticipated.
onsequently, a total of 74 patients provided 81% power to
etect a 4% absolute difference in NIHA%, with a signifi-
ance level of 0.05. Allowing for 25% attrition due to lack of
ollow-up angiography and insufficient IVUS quality, we
alculated that 100 patients would need to be enrolled.
Data are presented as frequencies or mean  SD.
omparisons between the SES and the PES were per-
ormed with the 2-tailed, unpaired t test or the Mann-
hitney test for continuous parameters, the paired t test for
hange from post-procedure to follow-up, and the Fisher
xact test for categorical variables. Correlations between
IHA and PSPA% post-procedure and between angio-
raphic LL and NIHA% were performed by linear regres-
ion analysis. Significance was set at an alpha of 0.05.
esults
etween May 2004 and April 2005, 101 patients were
nrolled in the study. Figure 1 depicts the flow of partici-
stent.luting
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Cypher Versus Taxus in Complex Lesions: The IVUS Study February 6, 2007:539–46ants throughout the study. Complete IVUS analysis was
btained in 42 patients receiving the SES and 43 receiving
he PES.
No significant differences in baseline clinical and angio-
raphic characteristics between the 2 groups were found
Tables 1 and 2). The degree of coronary atherosclerosis was
ndicated by the high prevalence of multivessel disease
75.3%), previous myocardial infarction (30.6%), and dia-
etes mellitus (24.7%), and by lesion length (mean 20.6 
.4 mm, range 12 to 49 mm). A trend toward a larger RVD
n the PES group was found (p  0.09).
Procedural characteristics, including the number of stents
er lesion, stent diameter and length, and the rate of direct
tenting, were also similar between the 2 groups (Table 2).
elivery of the single long stent initially chosen failed in 2
ES and 1 PES patients (p  0.2).
VUS results. Mean vessel, stent, and lumen areas were
imilar in the SES and PES groups, both after stent
mplantation and at 9-month follow-up (Table 3). The
hanges in mean vessel, plaque, and lumen areas at
ollow-up are represented in Figure 2. Mean lumen area
howed a significant reduction in both groups (p  0.004
nd p  0.001, for the SES and PES groups, respectively),
elated to the development of neointimal hyperplasia. The
eduction in lumen area at follow-up was significantly
igher in the PES group (p  0.002). Conversely, NIHA
nd NIHA%, the primary end point of the study, were
ignificantly smaller in the SES group (p  0.001). The
tent length free of IVUS-detectable neointimal hyperplasia
as significantly shorter in the PES group (p  0.001).
ore than 75% of stent length was neointimal hyperplasia-
ree in 59.5% of SES versus 25.6% of PES (p  0.002),
hile less than 25% of stent length was neointimal
yperplasia-free in 9.5% of SES versus 41.9% of PES (p 
.001). Neointimal hyperplasia-free stent length was in-
ersely correlated with NIHA% in both SES and PES (p 
.001) (Fig. 3).
Mean vessel area and PSPA in the SES group showed a
rend toward a reduction at follow-up (p  0.14 and p 
.09, respectively), while in the PES group they showed no
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Characteristics
SES,
42 Patients
PES,
43 Patients p Value
Age (yrs) 61  11 64  10 0.12
Male gender, n (%) 36 (85.7) 34 (79.1) 0.2
Current smoker, n (%) 20 (47.6) 18 (41.9) 0.2
Diabetes mellitus, n (%) 13 (31.0) 8 (18.6) 0.19
Hypertension, n (%) 28 (66.7) 26 (60.5) 0.2
Hyperlipidemia, n (%) 30 (71.4) 26 (60.5) 0.2
Dialysis, n (%) 3 (7.1) 0 (0) 0.12
Previous myocardial infarction, n (%) 15 (35.7) 11 (25.6) 0.2
Acute coronary syndrome, n (%) 19 (45.2) 22 (51.2) 0.2
Multivessel disease, n (%) 31 (73.8) 33 (76.7) 0.2
Left ventricular ejection fraction (%) 50  8 51  8 0.2sES  paclitaxel-eluting stent; SES  sirolimus-eluting stent.ignificant change (Table 3, Fig. 2). In terms of PSPA%, the
eduction in the SES group from post-procedure to
ollow-up reached statistical significance (p  0.008), mak-
ng the mean change in PSPA% from post-procedure to
ollow-up significantly different between the SES and PES
roups (2.1  4.8% vs. 0.1  3.4%, respectively; p 
.01). No correlation was found between NIHA at
ollow-up and PSPA% post-procedure (r 0.062, p 0.2).
An in-stent MLA of 6 mm2 after implantation (72.6%
s. 74.4%, in SES and PES groups, respectively; p  0.2)
as associated with no target-lesion revascularization dur-
ng follow-up (0% vs. 9.2%; p  0.06), and with minimal
inary in-stent restenosis (1.6% vs. 13.6%; p  0.05),
ompared with an in-stent MLA 6 mm2.
Incomplete stent apposition was comparable in the SES
nd PES groups, both after implantation (7.1% vs. 9.3%,
espectively; p  0.2) and at 9 months (14.3% vs. 11.7%;
 0.2), being persistent in 4.8% versus 4.7% of patients in
he SES and PES groups, respectively (p  0.2), and
ate-acquired in 9.5% versus 7.0% (p  0.2). Incomplete
pposition was never associated with a major adverse cardiac
vent.
ngiographic results. The mean in-stent LL at follow-up
as 0.16 0.19 mm in the SES group and 0.32 0.33 mm
n the PES group (p  0.003) (Table 4). The mean percent
aseline Angiographicharacteristics and Procedural Results
Table 2 Baseline AngiographicCharacteristics and Procedural Results
Characteristics
SES,
42 Lesions
PES,
43 Lesions p Value
ACC/AHA lesion class, n (%)
B2 24 (57.1) 28 (65.1) 0.2
C 18 (42.9) 15 (34.9) 0.2
Bifurcated lesion, n (%) 5 (11.9) 4 (9.3) 0.2
Ostial lesion, n (%) 2 (4.8) 2 (4.7) 0.2
Severe calcification, n (%) 1 (2.4) 0 (0) 0.2
Before procedure
Lesion length (mm) 21.2 11.2 20.1 7.2 0.2
Diameter of reference vessel (mm) 2.80 0.23 2.91 0.37 0.09
Minimal luminal diameter (mm) 0.95 0.27 0.86 0.42 0.2
Stenosis (%) 66.2 8.6 70.8 13.6 0.17
Chronic total occlusion, n (%) 1 (2.4) 3 (7.0) 0.2
During procedure
Maximal stent diameter (mm) 3.0 0.2 3.1 0.3 0.2
Mean number of stents, n 1.19 0.40 1.09 0.29 0.20
Total stent length (mm) 26.6 10.6 24.8 8.0 0.2
Direct stenting, n (%) 17 (40.5) 19 (44.2) 0.2
Unsuccessful initial implantation,
n (%)*
2 (4.8) 1 (2.3) 0.2
Final treatment success, n (%) 42 (100) 43 (100) 0.2
Immediately after procedure
Final in-stent minimal luminal
diameter (mm)
2.64 0.38 2.72 0.47 0.2
Final in-stent stenosis (%) 5.5 11.9 6.7 10.5 0.2
Defined as unsuccessful implantation of the first single stent chosen to cover the whole lesion.
ACC/AHA American College of Cardiology/American Heart Association; other abbreviations as
n Table 1.tenosis was quite low in both groups (10.7% vs. 16.8% for
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February 6, 2007:539–46 Cypher Versus Taxus in Complex Lesions: The IVUS Studyhe SES and PES groups, respectively; p  0.04), with a
ate of in-stent binary restenosis of only 2.4% versus 7.0% (p
0.2). With 5-mm proximal and distal stent margins, the
ate of in-segment restenosis was 2.4% versus 9.3%, for the
ntravascular Ultrasound Measurements
Table 3 Intravascular Ultrasound Measurements
In-Stent
SES,
42 Lesions
PES,
43 Lesions p Value
Vessel area (mm2)
Post-procedure 16.08 5.55 15.69 3.61 0.2
9-month follow-up 15.30 4.04 15.73 3.70 0.2
p Value 0.14 0.20
Stent area (mm2)
Post-procedure 8.13 2.46 8.23 1.86 0.2
9-month follow-up 8.07 1.80 8.21 1.78 0.2
p Value 0.20 0.20
Lumen area (mm2)
Post-procedure 8.13 2.46 8.23 1.86 0.2
9-month follow-up 7.46 1.60 7.01 1.94 0.2
p Value 0.004 0.001
Peri-stent plaque area (mm2)
Post-procedure 7.95 3.62 7.46 2.30 0.2
9-month follow-up 7.23 2.79 7.52 2.49 0.2
p Value 0.09 0.20
Peri-stent plaque area (%)
Post-procedure 48.1 8.0 46.9 6.9 0.2
9-month follow-up 46.0 7.9 47.0 7.1 0.2
p Value 0.008 0.20
Neointimal hyperplasia area
(mm2)
9-month follow-up 0.61 0.41 1.20 0.56 0.001
Neointimal hyperplasia area
(%)
9-month follow-up 7.4 4.2 15.4 8.1 0.001
Neointimal hyperplasia-free
stent length (%)
9-month follow-up 69.8 29.4 43.9 34.8 0.001
bbreviations as in Table 1.
Figure 2 Comparison of Changes in Vessel, Plaque,
and Lumen Areas Between SES and PES
Averaged changes (follow-up minus post-procedure) in vessel, plaque,
and lumen areas in the stented segment. Abbreviations as in Figure 1.AES and PES groups, respectively (p  0.2). A highly
ignificant linear correlation between angiographic LL and
IHA% was observed in the entire population (r  0.567,
 0.001).
ajor adverse cardiac events. The overall rate of major
dverse cardiac events was very low and not statistically
ifferent in both groups (4.8% vs. 6.8%, for the SES vs. the
ES, respectively; p 0.2), with 1 cardiac death in the PES
roup (0% vs. 2.3%, for the SES vs. the PES, respectively;
 0.2), and 1 myocardial infarction and 1 target-lesion
evascularization in each group (2.4% vs. 2.3%; p  0.2).
iscussion
ot surprisingly, in light of previous angiographic and
linical studies in short lesions, the present study demon-
trates that the SES reduces neointimal tissue proliferation
ignificantly more than the PES in long, complex coronary
esions. However, the NIHA% was remarkably low for both
ypes of drug-eluting stents, compared with previous data
n bare-metal stents (30% to 40%) (10,15), and in agree-
ent with previously reported IVUS data on the SES
2,4–8) and the PES (3,9,10,16,17).
In particular, in our SES population, with a mean lesion
ength 21.2 mm, the NIHA% was 7.4%, which is higher
Figure 3 Correlation of Neointimal Hyperplasia-Free Stent
Length and Neointimal Hyperplasia Area Percent
Correlation of percent neointimal hyperplasia-free stent length and percent neo-
intimal hyperplasia area in paclitaxel (solid circles  solid regression line) and
sirolimus-eluting stents (open diamonds  dashed regression line).
ngiographic Results at Follow-Up
Table 4 Angiographic Results at Follow-Up
Variable
SES,
42 Lesions
PES,
43 Lesions p Value
Diameter of reference vessel, mm 2.79 0.29 2.85 0.38 0.2
Minimal luminal diameter, mm 2.48 0.44 2.39 0.58 0.2
Stenosis, % 10.7 14.2 16.8 13.2 0.04
Late luminal loss, mm 0.16 0.19 0.32 0.33 0.003
In-stent binary restenosis, % 2.4 7.0 0.2
In-segment binary restenosis, % 2.4 9.3 0.2bbreviations as in Table 1.
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Cypher Versus Taxus in Complex Lesions: The IVUS Study February 6, 2007:539–46han that reported with SESs for shorter lesions at 8 to 12
onths follow-up: 2.3% was reported in the first series from
ão Paulo, Brazil (mean lesion length 12.9 mm) (4), 1% in
he RAVEL (RAndomized study with the sirolimus-eluting
Elocity balloon-expandable stent in the treatment of
atients with de novo native coronary artery Lesions) trial
mean lesion length of 14.4 mm) (7), 1.2% in the E-SIRIUS
European Sirolimus-Eluting Stent in Coronary Lesions)
rial (mean lesion length of 15.5 mm) (18), and 3.1% in the
IRIUS (Sirolimus-Eluting Stent in Coronary Lesions)
rial (mean lesion length of 14.4 mm) (2). Interestingly, in
he first series by São Paulo, NIHA% appeared to increase
o 6.6% at 2 years follow-up (5), and to 7.9% at 4 years (6).
Regarding the PES, in our population with mean lesion
ength 20.1 mm, the NIHA% (15.4%) was higher than the
.8% reported in the TAXUS-II trial with a mean lesion
ength 10.6 mm (3), but similar to the 12.2% of the
AXUS-IV trial (mean lesion length 12.5 mm) (10), and
he 13.1% of the TAXUS-V trial (mean lesion length
7.3 mm) (17).
The present study describes, for the first time in the
iterature, a direct comparison of IVUS results after SES
nd PES implantation for long lesions. Most published
VUS reports involve short lesions treated with a single SES
4–8) or PES (3,9,10). Fewer IVUS data involve more
omplex lesions, with use of multiple SESs (2,18) or PESs
17). The only randomized comparison of the SES and the
ES in complex lesions, the CORPAL (Drug-Eluting
tent for Complex Lesions) trial, has only been presented
rally (19).
The length of stent free of IVUS-evident neointimal
yperplasia has been reported to be greater in a non-
olymeric PES than in the corresponding bare-metal stent,
nd to correlate inversely with NIHA% (20). In the present
tudy, the inverse correlation with NIHA% was confirmed
oth for Cypher and Taxus stents (p  0.001). Interest-
ngly, the mean neointimal hyperplasia-free stent length in
ES was almost double than in PES (p  0.001), and
VUS-detectable neointimal hyperplasia was observed in
ver 75% of stent length in 41.9% of PES versus only 9.5%
f SES (p  0.001). Thus, neointimal hyperplasia inside
ES is often represented along the entire stent length, while
ES appear neointimal hyperplasia-free for most of their
ength. However, since the assessment of stent endotheliza-
ion is below the resolution of IVUS (20), the absence of
VUS-detectable hyperplasia does not imply the absence of
e-endothelization.
There was no correlation between neointimal hyperplasia
nd post-procedural peri-stent plaque burden in our study.
his finding is in agreement with previous reports showing
hat suppression of neointimal proliferation occurs irrespec-
ive of residual plaque burden after procedures with both the
ES (21) and the PES (9). Late-acquired incomplete stent
pposition was infrequent in both the SES and PES groups
9.5% vs. 7.0%, p  0.2) in the current study, which is
onsistent with a recent large, retrospective study by Hong Ct al. (22), indicating a prevalence of 13.2% with the SES
nd 8.4% with the PES in a real-world population. The
umber of patients with late-acquired incomplete stent
pposition in our study was too small to draw any conclu-
ions about its possible mechanism or clinical relevance.
Although the absolute changes in vessel and plaque area
rom baseline to follow-up in the current study were small
nd did not reach statistical significance, the reduction in
SPA% in the SES group was significant. This finding is in
ontrast with previous reports showing no such variations at
-month follow-up (7,8). However, at 4-year follow-up
fter SES implantation, a significant negative vessel remod-
ling behind the stent struts has been described (23). With
egard to PES, we did not observe significant changes in
SPA%, which is in agreement with the TAXUS-IV trial
10). On the contrary, an IVUS subanalysis of the
AXUS-II trial showed a significant increase in PSPA at 6
onths (9), although this increase regressed at 2-year
ollow-up (16).
In our opinion, factors other than the stent-eluted drug
ay play a major role in peri-stent plaque changes. We
ecently demonstrated that treatment with simvastatin 20
g/day in normocholesterolemic patients undergoing bare-
etal stent implantation significantly reduces PSPA% com-
ared with placebo (14% vs.6%) (15). This observation,
ogether with the apparent clinical benefits of statin treat-
ent, underlies the aggressive lipid-lowering approach
aiming for an low-density lipoprotein cholesterol level
110 mg/dl) we routinely use with all patients undergoing
oronary interventions. At follow-up, 93% of SES patients
nd 95% of PES patients were on statins. Statin treatment
ay play a role in the observed reduction in PSPA% in the
ES group in our study, and may mask the positive
emodeling tendency described with the PES in the
AXUS II trial (3).
An MLA 6 mm2 has been reported to reduce the risk
f target-lesion revascularization and qualifies as an “opti-
al IVUS result” (12). In our SES and PES populations, an
LA 6 mm2 post-procedure was associated with a very
ow rate of angiographic binary in-stent restenosis (1.6% vs.
3.6%; p  0.05), and with no need for target-lesion
evascularization during follow-up.
In agreement with the IVUS findings, quantitative an-
iography in our study showed a significantly lower LL with
he SES than the PES (0.16  0.19 mm vs. 0.32  0.33
m). In fact, a tight linear correlation between NIHA%
nd LL was observed (p  0.001). In-stent LL values are
omparable to those reported in other randomized trials
omparing the SES and the PES, such as the SIRTAX
Sirolimus-Eluting Stent Compared With Paclitaxel-
luting Stent for Coronary Revascularization) trial (0.12 
.36 mm vs. 0.25  0.49 mm with the SES and the PES,
espectively; p  0.001) (24), the ISAR-DIABETES
Paclitaxel-Eluting Stent Versus Sirolimus-Eluting Stent
or the Prevention of Restenosis in Diabetic Patients With
oronary Artery Disease) trial (0.19  0.44 mm vs. 0.46 
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andomized Multi-Center Head-to-Head Comparison of
he Sirolimus-Eluting Stent [Cypher] and the Paclitaxel-
luting Stent [Taxus]) trial (0.09  0.43 mm vs. 0.31 
.44 mm; p  0.001) (26). Angiographic restenosis rates in
he present study were also similar to those reported in the
iterature, but the population size was too small to allow
eaningful considerations.
The present study was not powered to detect differences
n clinical end points; however, the rate of major adverse
ardiac events was low and comparable between the 2
roups. Our data confirm the results of subgroup analyses of
atients with a stenosis in the left anterior descending artery
n the SIRIUS (27) and TAXUS-IV (28) trials, showing a
-year binary in-stent restenosis rate of 2.0% and 8.7%,
espectively, and a target-lesion revascularization rate of
.0% and 5.8%, respectively. In a recent meta-analysis of 6
andomized trials comparing the clinical and angiographic
utcome of SES and PES implantation, Kastrati et al. (29)
oncluded that patients receiving the SES have a signifi-
antly lower risk of restenosis and target-vessel revascular-
zation. However, until results of a multicenter study with
n adequately powered clinical end point are available, the
ES and the PES should be considered clinically equivalent.
This study is limited by the absence of an IVUS core lab.
owever, we perform an average of 150 IVUS examinations
er year, thus providing reliable expertise in the evaluation
f IVUS images. Secondly, the identification of the external
lastic membrane beyond the stent struts can be difficult or
ven impossible due to acoustic shadowing and presence of
ide branches, making the measurement of vessel volumes
nreliable. In order to improve the quality of our data, we
xcluded those patients in whom the external elastic mem-
rane could not be identified in 75% of stent length, and
alculated the mean vessel area as the ratio of vessel volume
o the actually analyzed length. We also acknowledge that
he inclusion of patients with acute coronary syndromes and
he discretional administration of glycoprotein IIb/IIIa
nhibitors may have had confounding effects on neointimal
roliferation. Finally, the sample size was too small to
ompare the clinical outcome, which was not an end point
f the study, but it was adequate for the prespecified
omparison of neointimal hyperplasia.
Whether or not the use of the SES (with the lower
eointimal hyperplasia formation) provides superior clinical
utcomes in the prognostically important left anterior de-
cending artery cannot be answered in this study but is
ertainly an area deserving further investigation in future
tudies.
onclusions. The present study demonstrates that both
he SES and the PES cause limited neointimal hyperplasia
n complex lesions, with a significant difference in favor of
he SES. Comparison with IVUS data obtained in previous
tudies involving shorter lesions shows a higher neointimal
et volume obstruction for both the SES and PES in more
omplex lesions, and this was particularly evident for theES. The difference in neointimal hyperplasia observed
etween the SES and the PES in the present study,
owever, does not translate into higher rates of angiographic
n-stent and in-segment restenosis.
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